Claudio Vinegoni

Claudio Vinegoni

Auto-generated profile, based on publicly available information

Claudio Vinegoni

Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, USA

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2012 in Nature
Verified
Journal Article
Open access
PDF file
PDPartha Dutta
Partha Dutta
Gabriel CourtiesGabriel Courties
Gabriel Courties
YWYing Wei
Ying Wei
FLFlorian Leuschner
Florian Leuschner
RGRostic Gorbatov
Rostic Gorbatov
MNMatthias Nahrendorf
Matthias Nahrendorf
During progression of atherosclerosis, myeloid cells destabilize lipid-rich plaques in the arterial wall and cause their rupture, thus triggering myocardial infarction and stroke. Survivors of acute coronary syndromes have a high risk of recurrent events for unknown reasons. Here we show that the systemic response to ischaemic injury aggravates chronic atherosclerosis. After myocardial infarction or stroke, Apoe−/− mice developed larger atherosclerotic lesions with a more advanced morphology. This disease acceleration persisted over many weeks and was associated with markedly increased monocyte recruitment. Seeking the source of surplus monocytes in plaques, we found that myocardial infarction liberated haematopoietic stem and progenitor cells from bone marrow niches via sympathetic nervous system signalling. The progenitors then seeded the spleen, yielding a sustained boost in monocyte production. These observations provide new mechanistic insight into atherogenesis and provide a novel therapeutic opportunity to mitigate disease progression.

1 April 2017 in Cell
Verified
Journal Article
Closed access
MHMaarten Hulsmans
Maarten Hulsmans
Sebastian ClaussSebastian Clauss
Sebastian Clauss
LXLing Xiao
Ling Xiao
AAAaron D. Aguirre
Aaron D. Aguirre
KKKevin R. King
Kevin R. King
MNMatthias Nahrendorf
Matthias Nahrendorf

22 June 2014 in Nature Medicine
Verified
Journal Article
Open access
PDF file
THTimo Heidt
Timo Heidt
HSHendrik B Sager
Hendrik B Sager
Gabriel CourtiesGabriel Courties
Gabriel Courties
PDPartha Dutta
Partha Dutta
YIYoshiko Iwamoto
Yoshiko Iwamoto
MNMatthias Nahrendorf
Matthias Nahrendorf
Activation of bone marrow hematopoietic stem cells by chronic stress raises circulating leukocyte levels and increases atherosclerotic plaque inflammation. Exposure to psychosocial stress is a risk factor for many diseases, including atherosclerosis1,2. Although incompletely understood, interaction between the psyche and the immune system provides one potential mechanism linking stress and disease inception and progression. Known cross-talk between the brain and immune system includes the hypothalamic-pituitary-adrenal axis, which centrally drives glucocorticoid production in the adrenal cortex, and the sympathetic-adrenal-medullary axis, which controls stress-induced catecholamine release in support of the fight-or-flight reflex3,4. It remains unknown, however, whether chronic stress changes hematopoietic stem cell activity. Here we show that stress increases proliferation of these most primitive hematopoietic progenitors, giving rise to higher levels of disease-promoting inflammatory leukocytes. We found that chronic stress induced monocytosis and neutrophilia in humans. While investigating the source of leukocytosis in mice, we discovered that stress activates upstream hematopoietic stem cells. Under conditions of chronic variable stress in mice, sympathetic nerve fibers released surplus noradrenaline, which signaled bone marrow niche cells to decrease CXCL12 levels through the β3-adrenergic receptor. Consequently, hematopoietic stem cell proliferation was elevated, leading to an increased output of neutrophils and inflammatory monocytes. When atherosclerosis-prone Apoe−/− mice were subjected to chronic stress, accelerated hematopoiesis promoted plaque features associated with vulnerable lesions that cause myocardial infarction and stroke in humans.

27 August 2018 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
FHFanny Herisson
Fanny Herisson
VFVanessa Frodermann
Vanessa Frodermann
Gabriel CourtiesGabriel Courties
Gabriel Courties
DRDavid Rohde
David Rohde
YSYuan Sun
Yuan Sun
MNMatthias Nahrendorf
Matthias Nahrendorf

21 June 2009 in Nature Photonics
Verified
Journal Article
Closed access
DRDaniel Razansky
Daniel Razansky
MDMartin Distel
Martin Distel
CVClaudio Vinegoni
Claudio Vinegoni
RMRui Ma
Rui Ma
NPNorbert Perrimon
Norbert Perrimon
VNVasilis Ntziachristos
Vasilis Ntziachristos

16 January 2018 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
MHMaarten Hulsmans
Maarten Hulsmans
HSHendrik B. Sager
Hendrik B. Sager
JRJason D. Roh
Jason D. Roh
MVMaría Valero-Muñoz
María Valero-Muñoz
NHNicholas E. Houstis
Nicholas E. Houstis
MNMatthias Nahrendorf
Matthias Nahrendorf
Macrophages populate the healthy myocardium and, depending on their phenotype, may contribute to tissue homeostasis or disease. Their origin and role in diastolic dysfunction, a hallmark of cardiac aging and heart failure with preserved ejection fraction, remain unclear. Here we show that cardiac macrophages expand in humans and mice with diastolic dysfunction, which in mice was induced by either hypertension or advanced age. A higher murine myocardial macrophage density results from monocyte recruitment and increased hematopoiesis in bone marrow and spleen. In humans, we observed a parallel constellation of hematopoietic activation: circulating myeloid cells are more frequent, and splenic 18F-FDG PET/CT imaging signal correlates with echocardiographic indices of diastolic dysfunction. While diastolic dysfunction develops, cardiac macrophages produce IL-10, activate fibroblasts, and stimulate collagen deposition, leading to impaired myocardial relaxation and increased myocardial stiffness. Deletion of IL-10 in macrophages improves diastolic function. These data imply expansion and phenotypic changes of cardiac macrophages as therapeutic targets for cardiac fibrosis leading to diastolic dysfunction.